Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Jacquie Ross; Senior Vice President - Treasury, Investor Relations; Gilead Sciences Inc. Daniel O'Day; Chairman, Chief Executive Officer; Gilead Sciences Inc. Johann ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

Morgan Stanley raised the firm’s price target on Gilead (GILD) to $135 from $130 and keeps an Overweight rating on the shares. The company ...

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th ESCMID Global conference in Vienna, Austria.